Aptamer Group signs agreement worth up to £155,000

Aptamer Group

Aptamer Group plc (LON: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced the signing of a new development contract with a rare disease biopharmaceutical company. The agreement, worth up to £155,000, focuses on developing two Optimer binders as critical reagents for therapeutic monitoring. Upon successful development, Aptamer could receive a significant undisclosed IP transfer fee for the use of the Optimers in clinical trial monitoring.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: “This agreement further demonstrates our strategic model of leveraging fee-for-service revenue for the development of Optimer binders and potential licensing revenues.

With a healthy pipeline and increasing traction among both new and repeat customers, we are demonstrating our commercial strategy. These advancements align with our broader vision of driving shareholder value by pairing fee-for-service income with scalable licensing opportunities. We remain focused on delivering on our growth objectives and look forward to sharing updates on our continued progress.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group extends Unilever collaboration for deodorant Optimers

    Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

    Aptamer Group raises £2.0 million in share placing

    Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.

    Aptamer Group raises £2m to fund growth

    Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

    Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

    Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.

    Aptamer expands odour control collaboration with Unilever

    Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.

      Search

      Search